造血干细胞移植术后儿童感染新型冠状病毒Omicron的临床特征分析

摘要
图/表
参考文献
相关文章 (5)

全文:PDF(1856 KB)HTML(1 KB)
输出:BibTeX|EndNote(RIS)

摘要目的：探讨接受造血干细胞移植术后儿童与无基础疾病正常儿童感染新型冠状病毒Omicron（以下简称Omicron）后临床特征差异性。方法：回顾性分析2022年12月―2023年1月感染Omicron儿童的临床资料,将接受造血干细胞移植儿童81例纳入移植组,无基础疾病正常儿童507例纳入正常组,比较两组患儿临床特征上的差异。结果：移植组与正常组年龄性别均无统计学差异。两组感染Omicron后主要症状均表现为发热,移植组64例（79.0%）正常组389例（76.7%）;其次为咳嗽,移植组57例（70.4%）正常组306例（60.4%）,两组发热和咳嗽症状比较均无统计学意义。同时移植组出现高热（34.6% vs 36.7%）、呼吸困难（4.9% vs 2.8%）、鼻塞（43.2% vs 46.5%）、咽痛（35.8% vs 28.4%）与正常组差异均无统计学意义。但移植组出现胃肠道不适（50.6% vs 27.2%）、败血症（3.7% vs 0.2%）、须使用呼吸支持治疗（3.7% vs 0%）、总病程超过2周（43.2% vs 10.1%）均明显高于正常组。结论：移植组和正常组患儿感染Omicron后均以轻型为主,但移植患儿中型或以上较严重感染比正常儿童更高,且病程更长。接受造血干细胞移植术后的感染患儿仍须积极预防重症感染及严重不良事件的发生。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	吴帅
	曾敏慧
	贺晶
	田鑫
	陈可可
	贺湘玲

关键词：儿童,造血干细胞移植,新型冠状病毒,Omicron,临床特征

Abstract：ObjectiveTo investigate the difference of clinical features between children who received hematopoietic stem cell transplantation and normal children without underlying diseases infected with Omicron variant of SARS-CoV-2(hereinafter referred to as Omicron).MethodsClinical data on Omicron-infected children from 2022-12-01 to 2023-1-20 were analyzed retrospectively. Eighty-one children who had received hematopoietic stem cell transplants were included in the transplant group, and 507 normal children without underlying medical conditions were included in the normal group. The differences in clinical characteristics between the two groups were compared.ResultsThere were no significant differences in age or gender between the transplant group and the normal group. The main symptom of Omicron infection in both groups was fever, 64 cases (79.0%) in the transplantation group compared with 389 cases (76.7%) in the normal group. The second most common symptom was cough, 57 cases (70.4%) in the transplantation group were compared with 306 cases (60.4%) in the normal group. There was no statistical significance in fever and cough symptoms between the two groups. At the same time, there were no significant differences between the transplantation group and the normal group in high fever (34.6% vs 36.7%), dyspnea (4.9% vs 2.8%), nasal congestion (43.2% vs 46.5%), and sore throat (35.8% vs 28.4%). In addition, gastrointestinal discomfort (50.6% vs 27.2%), sepsis (3.7% vs 0.2%), respiratory support (3.7% vs 0%), and total disease duration over 2 weeks (43.2% vs 10.1%) in the transplant group were significantly higher than those in the normal group.ConclusionOmicron infection was mainly mild in both the transplant and normal groups, but the incidence of moderate to severe infection was higher in the transplant group than in the normal group, and the duration of the disease was longer. Infected children following hematopoietic stem cell transplantation should still be actively prevented from serious infections and serious adverse events.

Key words：children hematopoietic stem cell transplantation SARS-CoV-2 Omicron clinical features

收稿日期:2023-02-17

中图分类号:

R373.1

通讯作者:贺湘玲,E-mail：hexiangling@hunnu.edu.cn

引用本文:

吴帅, 曾敏慧, 贺晶, 田鑫, 陈可可, 贺湘玲. 造血干细胞移植术后儿童感染新型冠状病毒Omicron的临床特征分析[J]. 金宝搏官方188学报(医学版), 2023, 20(3): 71-74. WU Shuai, ZENG Minhui, HE Jing, TIAN Xin, CHEN Keke, HE Xiangling. Clinical features of SARS-CoV-2 Omicron variant infection in children after hematopoietic stem cell transplantation. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(3): 71-74.

链接本文:

http://yxb.hunnu.edu.cn/CN/或http://yxb.hunnu.edu.cn/CN/Y2023/V20/I3/71

[1] Ai J, Zhang H, Zhang Y, et al.Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost[J]. Emerg Microbes Infect, 2022, 11(1): 337-343.
[2] 张苡菲, 梁世山, 吴沛霖, 等.201例儿童新型冠状病毒Omicron变异株感染的临床特征分析[J]. 中国当代儿科杂志, 2023, 25(1): 5-10.
[3] Ullrich F, Hanoun C, Turki AT, et al.Early report on the severity of COVID-19 in hematologic patients infected with the SARS-CoV2 omicron variant[J]. Eur J Haematol, 2022, 09(4): 364-372.
[4] 中华人民共和国国家卫生健康委员会医政医管局. 关于印发新型冠状病毒感染诊疗方案 (试行第十版) 的通知 (国卫办医急函〔2023〕4号)[EB/OL]. https://www.gov.cn/zhengce/zhengceku/2023-01/06/content_5735343.htm
[5] Sarkar A, Omar S, Alshareef A, et al.The relative prevalence of the Omicron variant within SARS-CoV-2 infected cohorts in different countries: A systematic review[J]. Hum Vaccin Immunother, 2023, 19(1): 2212568
[6] Harrison AG, Lin T, Wang P.Mechanisms of SARS-CoV-2 Transmission and Pathogenesis[J]. Trends Immunol, 2020, 41(12): 1100-1115.
[7] Perlman S, Netland J.Coronaviruses post-SARS: update on replication and pathogenesis[J]. Nat Rev Microbiol, 2009, 7(6): 439-450.
[8] WHO. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern[EB/OL]. Available at: https: //www. who. int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529) -sars-cov-2-variant-of-concern.
[9] Guo Y, Han J, Zhang Y, et al.SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance[J]. Front Immunol, 2022, 29(13): 877101.
[10] Papanikolaou V, Chrysovergis A, Ragos V, et al.From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants[J]. Gene, 2022, 10(814): 146134.
[11] Fantini J, Yahi N, Colson P, et al.The puzzling mutational landscape of the SARS-2-variant Omicron[J]. J Med Virol, 2022, 94(5): 2019-2025.
[12] Ali EAH, Khamees I, Alshurafa A, et al.Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Patients with Philadelphia-Negative Myeloproliferative Neoplasm: A Single Center Experience[J]. Oncology, 2022, 100(8): 460-466.
[13] Ali EA, Khamees I, Abu-Tineh M, et al.SARS-CoV-2 Omicron Variant in Patients With Chronic Myeloid Leukemia: A Retrospective Study[J]. Cureus, 2022, 14(4): 23863.
[14] Ali EA, Alamin MA, Abu-Tineh M, et al.A Case Series of SARS-CoV-2 Omicron Variant in Patients With Acute Leukemia[J]. Cureus, 2022, 14(5): 25196.
[15] Malahe SRK, Hoek RAS, Dalm VASH, et al.Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational study[J]. Clin Infect Dis, 2022, 76(3): 172-178
[16] Nevejan L, Ombelet S, Laenen L, et al.Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts[J]. Viruses, 2022, 14(12): 2736.
[17] Cauchi JP, Dziugyte A, Borg ML, et al.Hybrid immunity and protection against infection during the Omicron wave in Malta[J]. Emerg Microbes Infect, 2023, 12(1): 2156814.
[18] Xu H, Li H, You H, et al.Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: real-world study in Jilin Province, China[J]. Emerg Microbes Infect, 2023, 12(1): 2149935.
[19] Blennow O, Salmanton-García J, Nowak P, et al.Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report[J]. Am J Hematol, 2022, 97(8): 312-317.